Merck & Co., Inc. (MRK): who owns it and who trades it
As of Nov 16, 2026, MRK insiders reported 34 open-market sales worth $79.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Zachary (Vice president), with $25.2M. 11 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Merck
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds and Congress were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MRK
3,806 funds and institutions reported MRK shares worth $254B at the end of Q2 2026, about 80% of the company. The largest holder is BlackRock, Inc. with 9.2%.
Funds and institutions (13F) 80%Everyone else 20%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 227.00M | 9.19% | $29.2B | +1% |
| Vanguard Capital Management LLC | 161.32M | 6.53% | $20.7B | +0% |
| State Street Corp | 120.41M | 4.88% | $15.6B | +1% |
| Wellington Management Group LLP | 86.25M | 3.49% | $11.1B | +2% |
| Vanguard Portfolio Management LLC | 67.74M | 2.74% | $8.7B | +1% |
| Geode Capital Management, LLC | 60.74M | 2.46% | $7.8B | +2% |
| Charles Schwab Investment Management Inc | 54.37M | 2.20% | $7B | +9% |
| Morgan Stanley | 48.64M | 1.97% | $6.3B | +2% |
| FMR LLC (Fidelity) | 45.44M | 1.84% | $5.8B | +2% |
| JPMorgan Chase & Co | 43.89M | 1.78% | $5.7B | – |
| Fisher Asset Management, LLC | 38.52M | 1.56% | $4.9B | +46% |
| Norges Bank | 36.98M | 1.50% | $4.8B | – |
| Bank of America Corp | 30.54M | 1.24% | $3.9B | -1% |
| Northern Trust Corp | 26.28M | 1.06% | $3.4B | -3% |
| Goldman Sachs Group Inc | 22.08M | 0.89% | $2.8B | +10% |
| Franklin Resources Inc | 19.55M | 0.79% | $2.5B | +20% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 19.55M | 0.79% | $2.5B | -4% |
| Legal & General Group Plc | 18.87M | 0.76% | $2.4B | -3% |
| Invesco Ltd. | 18.61M | 0.75% | $2.4B | -15% |
| T. Rowe Price Associates | 18.52M | 0.75% | $2.4B | -20% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MRK insiders reported $0 of open-market purchases and $79.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Richard R. DeLuca | Vice president | Sale | 58,185 | $148.01 | $8.6M | Form 4 |
| Aug 13, 2026 | Chirfi Guindo | Vice president | Sale | 10,000 | $135.00 | $1.4M | Form 4 |
| Aug 12, 2026 | Jennifer Zachary | Vice president | Sale | 80,315 | $133.46 | $10.7M | Form 4 |
| Aug 12, 2026 | Richard R. DeLuca | Vice president | Sale | 11,099 | $131.61 | $1.5M | Form 4 |
| Aug 12, 2026 | Richard R. DeLuca | Vice president | Sale | 600 | $132.04 | $79.2K | Form 4 |
| Aug 11, 2026 | Richard R. DeLuca | Vice president | Sale | 7,410 | $131.33 | $973K | Form 4 |
| Aug 11, 2026 | Richard R. DeLuca | Vice president | Sale | 5,427 | $132.35 | $718K | Form 4 |
| Aug 10, 2026 | Richard R. DeLuca | Vice president | Sale | 20,784 | $130.43 | $2.7M | Form 4 |
| Aug 6, 2026 | Richard R. DeLuca | Vice president | Sale | 805 | $131.02 | $105K | Form 4 |
| Aug 6, 2026 | Richard R. DeLuca | Vice president | Sale | 300 | $131.02 | $39.3K | Form 4 |
| Aug 6, 2026 | Richard R. DeLuca | Vice president | Sale | 4,945 | $130.23 | $644K | Form 4 |
| Aug 6, 2026 | Chirfi Guindo | Vice president | Sale | 15,000 | $131.00 | $2M | Form 4 |
| Aug 5, 2026 | David R. Maraldo | Vice president | Sale | 9,709 | $128.72 | $1.2M | Form 4 |
| Aug 5, 2026 | David R. Maraldo | Vice president | Sale | 2,686 | $128.72 | $346K | Form 4 |
| Aug 5, 2026 | David R. Maraldo | Vice president | Sale | 6,311 | $128.72 | $812K | Form 4 |
| Aug 5, 2026 | David Michael Williams | Vice president | Sale | 34,705 | $128.77 | $4.5M | Form 4 |
| Aug 5, 2026 | David Michael Williams | Vice president | Sale | 4,600 | $128.77 | $592K | Form 4 |
| Aug 5, 2026 | David Michael Williams | Vice president | Sale | 13,542 | $128.77 | $1.7M | Form 4 |
| Feb 12, 2026 | Chirfi Guindo | Chief Marketing Officer | Sale | 10,000 | $121.46 | $1.2M | Form 4 |
| Feb 10, 2026 | Dean Y Li | Vice president | Sale | 10,235 | $117.52 | $1.2M | Form 4 |
| Feb 9, 2026 | Chirfi Guindo | Chief Marketing Officer | Sale | 10,000 | $118.41 | $1.2M | Form 4 |
| Feb 9, 2026 | Jennifer Zachary | Vice president | Sale | 38,835 | $119.15 | $4.6M | Form 4 |
| Feb 9, 2026 | Jennifer Zachary | Vice president | Sale | 56,792 | $119.15 | $6.8M | Form 4 |
| Feb 9, 2026 | Jennifer Zachary | Vice president | Sale | 25,946 | $119.15 | $3.1M | Form 4 |
| Feb 6, 2026 | David Michael Williams | Vice president | Sale | 5,000 | $121.91 | $610K | Form 4 |
| Feb 6, 2026 | Johannes Jacobus Oosthuizen | President | Sale | 15,000 | $121.87 | $1.8M | Form 4 |
| Feb 6, 2026 | Richard R. DeLuca | Vice president | Sale | 37,685 | $120.92 | $4.6M | Form 4 |
| Feb 5, 2026 | Chirfi Guindo | Chief Marketing Officer | Sale | 20,000 | $121.88 | $2.4M | Form 4 |
| Feb 4, 2026 | Dalton E. Smart III | Vice president | Sale | 2,400 | $119.68 | $287K | Form 4 |
| Feb 4, 2026 | Dalton E. Smart III | Vice president | Sale | 4,000 | $119.68 | $479K | Form 4 |
| Feb 4, 2026 | Caroline Litchfield | CFO | Sale | 41,997 | $119.61 | $5M | Form 4 |
| Feb 4, 2026 | Dean Y Li | Vice president | Sale | 15,087 | $118.77 | $1.8M | Form 4 |
| Feb 4, 2026 | Robert M Davis | CEO | Sale | 14,972 | $117.38 | $1.8M | Form 4 |
| Feb 4, 2026 | Robert M Davis | CEO | Sale | 32,462 | $118.35 | $3.8M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jennifer Zachary | EVP, General Counsel | – | $25.2M | Aug 12, 2026 |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | – | $19.9M | Nov 12, 2026 |
| Chirfi Guindo | Chief Marketing Officer | – | $8.2M | Aug 13, 2026 |
| David Michael Williams | EVP,Chief Info&Digital Officer | – | $7.4M | Aug 5, 2026 |
| Robert M Davis | Chairman, CEO & President, Director | – | $5.6M | Feb 4, 2026 |
| Caroline Litchfield | EVP & CFO | – | $5M | Feb 4, 2026 |
| Dean Y Li | Executive VP & President, MRL | – | $3M | Feb 10, 2026 |
| David R. Maraldo | EVP & Pres. MMD | – | $2.4M | Aug 5, 2026 |
| Johannes Jacobus Oosthuizen | President, U.S. Market | – | $1.8M | Feb 6, 2026 |
| Dalton E. Smart III | SVP Fin. - Global Controller | – | $766K | Feb 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MRK short interest
Low short interest. 1.1% of MRK shares are sold short: about 1 share in 93. Over the last 12 reports the number of shares short went down 8%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 26.60M MRK shares were sold short, 1.1% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 11.29M shares, buying them all back would take about 2.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 26.60M | 1.08% | -1% | 11.29M | 2.4 |
| Oct 15, 2026 | 26.83M | 1.09% | -5% | 9.02M | 3.0 |
| Sep 30, 2026 | 28.27M | 1.15% | -18% | 11.19M | 2.5 |
| Sep 15, 2026 | 34.43M | 1.40% | +14% | 8.14M | 4.2 |
| Aug 31, 2026 | 30.29M | 1.23% | +24% | 13.56M | 2.2 |
| Aug 14, 2026 | 24.51M | 0.99% | -13% | 8.64M | 2.8 |
| Jul 31, 2026 | 28.28M | 1.15% | -4% | 8.70M | 3.2 |
| Jul 15, 2026 | 29.36M | 1.19% | -6% | 8.58M | 3.4 |
| Jun 30, 2026 | 31.38M | 1.27% | +4% | 13.65M | 2.3 |
| Jun 15, 2026 | 30.27M | 1.23% | -1% | 11.78M | 2.6 |
| May 29, 2026 | 30.55M | 1.24% | +5% | 9.99M | 3.1 |
| May 15, 2026 | 29.06M | 1.18% | +11% | 8.01M | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded MRK
Since Nov 17, 2024, 17 members of Congress reported 16 purchases and 22 sales of MRK. The latest was a sale by Maria Elvira Salazar on Sep 24, 2026, reported Oct 7, 2026.
Purchases 16Sales 22
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Maria Elvira Salazar (R-FL) | Partial sale | $1K–$15K | Self | Oct 7, 2026 | Report |
| Aug 19, 2026 | Maria Elvira Salazar (R-FL) | Purchase | $15K–$50K | Self | Sep 9, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Sale | $15K–$50K | Self | Jul 21, 2026 | Report |
| Feb 4, 2026 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Mar 16, 2026 | Report |
| Dec 19, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jan 12, 2026 | Report |
| Dec 18, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jan 15, 2026 | Report |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
| Nov 13, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Sep 23, 2025 | Val T. Hoyle (D-OR) | Sale | $1K–$15K | Spouse | Oct 10, 2025 | Report |
| Aug 28, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | Aug 29, 2025 | Report |
| Aug 14, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Sep 11, 2025 | Report |
| Aug 5, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 12, 2025 | Report |
| Aug 4, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| Jul 11, 2025 | Ritchie Torres (D-NY) | Sale | $1K–$15K | Self | Aug 20, 2025 | Report |
| Jun 24, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 16, 2025 | Scott Franklin (R-FL) | Sale | $1K–$15K | Joint | Jul 14, 2025 | Report |
| Jun 13, 2025 | Julie Johnson (D-TX) | Purchase | $1K–$15K | Joint | Jul 14, 2025 | Report |
| May 30, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Jun 6, 2025 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $15K–$50K | Self | May 31, 2025 | Report |
| May 5, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 29, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Apr 17, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | May 8, 2025 | Report |
| Apr 9, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | Apr 11, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $15K–$50K | Self | May 8, 2025 | Report |
| Mar 31, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $15K–$50K | Self | Apr 7, 2025 | Report |
| Mar 20, 2025 | Kelly Morrison (D-MN) | Partial sale | $1K–$15K | Self | Apr 11, 2025 | Report |
| Mar 19, 2025 | Sheri Biggs (R-SC) | Sale | $15K–$50K | Spouse | Oct 5, 2025 | Report |
| Mar 3, 2025 | Bruce Westerman (R-AR) | Purchase | $1K–$15K | Self | Apr 16, 2025 | Report |
| Feb 26, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $15K–$50K | Self | Mar 6, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $15K–$50K | Self | Mar 27, 2025 | Report |
| Feb 24, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Mar 9, 2025 | Report |
| Jan 27, 2025 | Josh Gottheimer (D-NJ) | Sale | $15K–$50K | Joint | Feb 10, 2025 | Report |
| Jan 24, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Feb 11, 2025 | Report |
| Jan 17, 2025 | Julie Johnson (D-TX) | Purchase | $1K–$15K | Joint | Feb 12, 2025 | Report |
| Jan 16, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Self | Feb 10, 2025 | Report |
| Jan 16, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Spouse | Feb 10, 2025 | Report |
| Jan 15, 2025 | Jared Moskowitz (D-FL) | Sale | $1K–$15K | Child | Feb 10, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Merck company events
Merck filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 13, 2026LeadershipIncorporated by reference is a press release issued by Merck & Co., Inc. on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors, effective November 1, 2026. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- May 28, 2026VoteReported shareholder vote results. Filing
- May 22, 2026AnnouncementMerck & Co., Inc. closed an underwritten public offering of $500 million of Floating Rate Notes due 2028, $1 billion of 4.300% Notes due 2028, $500 million of 4.650% Notes due 2031, $1 billion of 4.950% Notes due 2033, $1.5 billion of 5.200% Notes due 2036, $500 million of 5.750% Notes due 2046 and… Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 3, 2026ResultsReleased financial results. Filing
- Dec 4, 2025AnnouncementMerck & Co., Inc. closed an underwritten public offering of $500 million of Floating Rate Notes due 2029, $750 million of 3.850% Notes due 2029, $1 billion of 4.150% Notes due 2031, $1 billion of 4.450% Notes due 2032, $1.5 billion of 4.750% Notes due 2035, $750 million of 5.500% Notes due 2046… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How Merck makes money
Pharmaceutical brought in 90% of Merck's revenue ($58.1B of $64.5B) in 2025. Animal health was next, at 10%.
By business segment, 2025
By region, 2025
From Merck's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 24, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
Merck financials
Famous investors that hold MRK
11 of the 50 well-known investors we track reported holding MRK in their latest 13F filing. The largest position is Ken Fisher's, worth $6.1B.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 41.70M | $6.1B | 1.7% | +8% |
| Jeremy Grantham · GMO | Q3 2026 | 5.02M | $730M | 1.6% | -26% |
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 4.64M | $675M | 0.9% | -62% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 3.32M | $483M | 0.3% | +72% |
| Israel Englander · Millennium Management | Q3 2026 | 1.74M | $253M | 0.2% | +211% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.13M | $164M | 0.3% | +196% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 422,770 | $61.4M | 0.3% | New |
| Prem Watsa · Fairfax Financial Holdings | Q3 2026 | 172,900 | $25.1M | 0.9% | No change |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 39,293 | $5.7M | 0.0% | +30% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 4,357 | $633K | 0.0% | New |
| Tom Russo · Gardner Russo & Quinn | Q3 2026 | 1,643 | $239K | 0.0% | +0% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Merck & Co., Inc. (MRK) stock
Who owns the most MRK stock?
The largest reported owner of Merck & Co., Inc. (MRK) is BlackRock, Inc., with 9.2% of the company. In total, 3,806 funds and institutions reported holding MRK at the end of Q2 2026, together about 80% of the shares. See the largest owners.
Are MRK insiders buying or selling?
In the last 12 months, MRK insiders reported no open-market purchases and 34 sales worth $79.3M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in MRK?
As of Oct 30, 2026, 26.60M MRK shares were sold short, 1.1% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 11.29M shares, buying them all back would take about 2.4 trading days (days to cover). See the history.
Have members of Congress traded MRK?
Yes. 17 members of Congress reported 16 purchases and 22 sales of MRK since Nov 17, 2024. The latest was reported on Oct 7, 2026. See the trades.
How does Merck make money?
Pharmaceutical brought in 90% of Merck's revenue ($58.1B of $64.5B) in 2025. Animal health was next, at 10%. See the full split.
Which famous investors hold MRK?
11 of the 50 well-known investors we track reported MRK in their latest 13F filing, including Ken Fisher, Jeremy Grantham, Bill Nygren. The largest position is worth $6.1B. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.